-
Lilly’s Foundayo (orforglipron) Significantly Reduced Obstructive Sleep Apnea Severity, Reinforcing Its Potential to Improve Health Beyond Weight Loss
NYSE: $LLY INDIANAPOLIS, Nov. 9, 2026 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY), the maker of Zepbound (tirzepatide), today announced positive results from ATTAIN-OSA, a Phase 3 clinical program evaluating the efficacy and safety of Foundayo… Source: Read More
-
New Data on Lilly’s Investigational Treatment Olomorasib at ESMO 2026 Show Durable First-Line Activity in KRAS G12C-Mutant Non-Small Cell Lung Cancer
NYSE: $LLY INDIANAPOLIS, Oct. 25, 2026 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) today announced new first-line data on olomorasib, its investigational, next-generation KRAS G12C inhibitor, at the 2026 European Society for Medical Oncology… Source: Read More
-
A New Frontier in Weight Loss: Retatrutide vs. Ozempic
NYSE: $LLY The Next Generation of Diabetes and Obesity Treatment A recent clinical trial has sent waves through the medical community, showcasing promising results for Eli Lilly’s experimental drug, retatrutide. As the landscape for metabolic health evolves, this new “triple-hormone” receptor agonist is showing potential to outperform current market leaders like Ozempic. Understanding the Clinical…
-
A New Horizon in Metabolic Health: Understanding Lilly’s Retatrutide
NYSE: $LLY A Breakthrough in Weight Loss and Diabetes Management Eli Lilly and Company has recently unveiled promising clinical trial results for their investigational molecule, retatrutide, a GGG triple hormone receptor agonist. This compound represents a significant leap forward in the treatment of obesity and type 2 diabetes by targeting three distinct pathways simultaneously. Understanding…
-
A Breakthrough in Cancer Care: Jaypirca Receives Expanded FDA Approval
NYSE: $LLY A New Chapter for Patients with CLL and SLL The landscape of treatment for chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) has shifted significantly. Eli Lilly and Company recently announced that the U.S. Food and Drug Administration (FDA) has granted expanded approval for Jaypirca (pirtobrutinib). This milestone marks an important advancement…
-
New Hope: FDA Approves Inluriyo (Imlunestrant) Combination for Advanced Breast Cancer
NYSE: $LLY A New Frontier in Targeted Cancer Therapy The landscape of breast cancer treatment has taken a significant step forward with the recent FDA approval of Inluriyo (imlunestrant). This novel medication, used in combination with Verzenio (abemaciclib), offers a new targeted approach for specific patient populations battling advanced or metastatic breast cancer. Understanding the…
-
A New Milestone in Blood Cancer Treatment: FDA Expands Approval for Jaypirca
NYSE: $LLY A New Therapeutic Option for CLL/SLL Patients The landscape of blood cancer treatment has taken a significant step forward. The U.S. Food and Drug Administration (FDA) has granted expanded approval for Jaypirca (pirtobrutinib), marking it as the first and only non-covalent BTK inhibitor available for patients with previously untreated chronic lymphocytic leukemia (CLL)…
-
Eli Lilly Acquires Orna Therapeutics to Pioneer In Vivo Cell Engineering and Advance Next-Generation Therapies
NYSE: $LLY Eli Lilly and Company has announced a significant strategic move to bolster its capabilities in advanced therapeutics by entering into a definitive agreement to acquire Orna Therapeutics, Inc. This acquisition focuses on integrating Orna’s innovative platform for engineering immune cells directly within the body, aiming to revolutionize the treatment landscape for various diseases,…